/Investors

DCI Partners Co. Ltd.

Venture capital

Tokyo · Pre-Seed–Growth · 4 people tracked

Also known as 大和企業投資株式会社

Find your way into DCI Partners Co. Ltd.

62 people in our graph share verified history with the DCI Partners Co. Ltd. team — schools, employers, funds. One of them is your warm intro.

Sethu Chidambaramunlockedknows LingLing Liu(劉 玲玲) · together at Daiwa Securities Capital Markets (overlapped)
×3knows the team · via Daiwa Securities Capital Markets
×8knows the team · via Zhejiang University
✨ Fox Verdict
Sign up to see your fit

Investment thesis

DCI Partners is a specialized VC focused on drug discovery and regenerative medicine, building on more than 20 years of biotech investing experience dating from its NIF era (now Daiwa Corporate Investment). It operates one of the largest specialized funds of its kind in Japan, supplying risk capital to growth-stage companies poised to shape future industries. Beyond funding, the firm offers hands-on support drawing on expertise in clinical development, intellectual property, and business development, plus networks across research institutions, drug-discovery ventures, and pharmaceutical companies. It also leads the creation of new ventures from promising research seeds and collaborates across Japan and Taiwan to maximize portfolio potential.

Source: firm website, verified Aug 3, 2026.

Stage
Pre-Seed–Growth
Check
$4.3M – $71M
HQ
Tokyo, JP
Instruments
Equity
Founded
2014
AUM
$200M
Tracked investments
1

Team · 4 people

from the firm's website & public directories
LingLing Liu(劉 玲玲)in

Joined DCIP in 2015 after working as a financial advisor in Daiwa Securities' M&A division.

Hiroki Narita· President and CEO

What they invest in

from 1 of 1 portfolio companies

Biotech ×1Deep Tech ×1Healthtech ×1Longevity ×1

HQs:Japan×1

Investments · 2 tracked

founders shown can be your intro path
LUCA Scienceluca-science.comJun 2022

LUCA Science develops mitochondrial therapies that supply functional, storable mitochondria to damaged or dysfunctional cells and tissues to restore cellular energy production, targeting conditions such as ischemia-reperfusion injuries including cerebral and myocardial infarction.

BiotechDeep TechHealthtechLongevity

Co-investorsFast Track InitiativeRemiges Ventures, Inc.4BIO CapitalAstellas Venture Management LLCAxil Capital

株式会社AIメディカルサービスai-ms.comin𝕏Oct 2019

AI Medical Service Inc. develops AI systems that support image-based diagnosis of endoscopy, primarily for detecting gastrointestinal cancers such as stomach and esophageal cancer.

AI & Machine LearningDigital HealthHealthtechMedical DevicesTokyo, JP

Tomohiro Tada(Representative Director & Chief Medical Officer)inYasushi Takikawa(Representative Director)

Co-investorsGlobis Capital PartnersWiLJapan Post Capital Co. Ltd.SoftBank Vision FundSony Ventures Corporation

Frequently asked questions

What stage does DCI Partners Co. Ltd. invest at?
DCI Partners Co. Ltd. invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth stages.
What is DCI Partners Co. Ltd.'s typical check size?
DCI Partners Co. Ltd. typically writes checks of $4.3M – $71M.
What sectors does DCI Partners Co. Ltd. focus on?
DCI Partners Co. Ltd. focuses on Biotech, Digital Health, Healthtech, Medical Devices, SaaS, Sector Agnostic.
Where is DCI Partners Co. Ltd. located?
DCI Partners Co. Ltd. is headquartered in Tokyo, JP.

Images

DCI Partners Co. Ltd. photo

Similar investors

Featured in lists